MedPage Today January 18, 2025
— Analyses of current or former use, duration of use, social factors fail to show an association
Postmenopausal hormone therapy (HT) did not significantly increase the risk of glioma, leaving unresolved the reason for the sex disparity in incidence, a large retrospective analysis showed.
A review of data for 75,335 women produced a nonsignificant 16% increase in the hazard ratio for glioma among women with a history of HT. Analyses of current versus former use of HT and duration of HT showed no significant associations with glioma.
An extensive subgroup analysis revealed a positive association only for college-educated women, but a test for the interaction effect of education did not achieve statistical significance, reported Hui Tang, MD, of North Sichuan...
Today's Sponsors
Today's Sponsor